Ebola Fever Therapeutics, formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans. The virus is transmitted to people from wild animals and then spreads in the human population through human-to-human transmission. The natural host of the Ebola virus is believed to be fruit bats, a species found in Africa. After the virus enters the human population, it can spread through direct contact with blood, secretions, organs or other bodily fluids of infected people, and with surfaces and materials such as bedding and clothing contaminated with these fluids.
Supportive Care and New Therapeutic Approaches
As there is currently no licensed treatment for Ebola virus disease, care is supportive: fluid and electrolyte management with intravenous (IV) fluids and balance of nutrients, treating specific infections when they occur, maintaining oxygen status and blood pressure. However, research to develop medical countermeasures for EVD is ongoing. Several potential treatments are under development and evaluation. They include blood products, antiviral drugs, vaccine candidates, and specialized treatments.
Blood Products and Immunotherapies
Convalescent blood products or plasma collected from individuals who have recovered from EVD harbor antibodies that can help fight the virus. These products are being explored as a potential treatment for sick patients. Monoclonal antibodies, antibodies produced in a laboratory that can treat specific infections, also show promise against Ebola virus. One experimental treatment includes ZMapp, a cocktail of three monoclonal antibodies. In initial studies it improved survival when given to Ebola infected primates.
Antiviral Drugs
Several antiviral drugs are under investigation for Ebola Fever Therapeutics . BCX4430, an experimental drug developed by BioCryst Pharmaceuticals, acts against Ebola and other high-threat viruses. It has shown efficacy in both test tube and animal studies. Another investigational drug is favipiravir, approved in Japan to treat influenza. Studies in Ebola-infected primates demonstrated improved survival when given early in infection. Remdesivir, developed by Gilead Sciences, is a broad-spectrum antiviral currently in clinical trials for Ebola. It has shown safety and efficacy in non-human primates.
Vaccine Candidates
Developing a preventive Ebola vaccine is a priority. Several candidates have shown initial promise in early stages of clinical testing or in pre-clinical research in animals. rVSV-ZEBOV was the first vaccine approved for use during the recent outbreak in eastern regions of the Democratic Republic of Congo. RNA vaccines developed by Moderna and INOVIO Pharmaceuticals have also undergone initial human testing. Ad26.ZEBOV and MVA-BN-Filo are two additional preventive vaccine candidates in late-stage clinical evaluation. Success in these trials could pave the way for regulatory approval and stockpiling.
Specialized Ebola Treatments
Beyond supportive care and experimental therapies, some specialized Ebola Fever Therapeutics approaches have also been explored. These include using the protein APOBEC3G, which exerts broad-spectrum antiviral effects, plus triazine dyes that target specific virus proteins. Traditional herbal medicine with potential anti-Ebola activities is another area under investigation by researchers. While preliminary, continued research may validate these unique treatment strategies over time. Close collaboration between global health organizations remains essential to advance Ebola therapeutics through various stages of research and development.
Significant progress is underway to find safe and effective treatments to fight Ebola virus disease. Current care remains primarily supportive, but a combination of convalescent blood products, monoclonal antibodies, antiviral drugs, vaccine candidates and other specialized interventions offer hope. With continued research and coordinated international efforts, the goal of developing licensed medical countermeasures for EVD remains an urgent priority to save lives during future outbreaks and aid recovery of affected regions in Africa.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it

About Author - Money Singh
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc. LinkedIn Profile